CHEK1 and non-small cell lung carcinoma: A combination of CHK1 inhibitors such as SB218078 or AZD7762 potentiates the effect of conventional chemotherapy, including gemcitabine and cisplatin on NSCLC stem cells in vitro and in xenograft models [229].